iExosomes for Pancreatic Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests tiny particles from special cells carrying genetic material to treat pancreatic cancer patients with a specific mutation. The particles deliver this material into cancer cells to stop them from growing by silencing a harmful gene. Gene therapy is being explored as a novel treatment for pancreatic cancer, targeting specific genetic alterations to inhibit cancer progression.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, it does mention that patients with stable disease must have completed at least 4 months of chemotherapy, which might imply continuing some treatments. It's best to discuss your specific medications with the trial team.
Is iExosomes treatment safe for humans?
The research primarily focuses on the effectiveness of iExosomes in targeting pancreatic cancer in mice, but it does not provide specific safety data for humans. However, exosomes are naturally present in the blood, suggesting a potential for safety, though human-specific safety data is needed.12345
How is the iExosomes treatment for pancreatic cancer different from other treatments?
The iExosomes treatment is unique because it uses exosomes (tiny particles released by cells) derived from mesenchymal stromal cells to deliver KRAS G12D siRNA directly to cancer cells, specifically targeting a common mutation in pancreatic cancer. This approach enhances the treatment's effectiveness by protecting the exosomes from being destroyed by the immune system, allowing them to reach and suppress the cancer more efficiently than traditional methods.16789
What data supports the effectiveness of the treatment Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA for pancreatic cancer?
Research shows that exosomes (tiny particles that transport materials between cells) from mesenchymal stromal cells can effectively deliver siRNA (a type of genetic material that can silence specific genes) to pancreatic cancer cells, reducing their growth and spread. Additionally, these exosomes have been used to deliver other therapeutic agents, showing promise in targeting and treating pancreatic cancer.310111213
Who Is on the Research Team?
Brandon Smaglo, MD
Principal Investigator
M.D. Anderson Cancer Center
Are You a Good Fit for This Trial?
This trial is for adults with metastatic pancreatic cancer that has a specific mutation (KrasG12D). Participants must have tried at least one systemic therapy and have certain blood and organ function levels within normal ranges. Pregnant or breastfeeding individuals are excluded, as well as those with severe medical conditions or brain metastases unless treated and stable.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive mesenchymal stromal cells-derived exosomes with KrasG12D siRNA intravenously on days 1, 4, and 10, repeating every 14 days for up to 3 courses
Extended Treatment
Participants who respond may continue 3 additional courses of treatment
Follow-up
Participants are monitored for safety and effectiveness after treatment completion
What Are the Treatments Tested in This Trial?
Interventions
- Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor